SPATA2 is a bridging adaptor protein that functions as a critical regulator of TNF receptor signaling and cell death pathways. Primary Function: SPATA2 mediates the recruitment of the deubiquitinase CYLD to the linear ubiquitin chain assembly complex (LUBAC), specifically bridging RNF31/HOIP to CYLD at the TNF receptor signaling complex 1. Mechanism: SPATA2 interacts via its PUB domain with CYLD while its PIM (PUB interaction motif) engages HOIP, thereby enabling CYLD-mediated deubiquitination of Met1- and Lys63-linked ubiquitin chains on RIPK1 12. This deubiquitination activity attenuates NF-κB and MAPK signaling while promoting TNF-induced necroptosis and apoptosis 1. Disease Relevance: SPATA2 deficiency results in increased TNF-mediated NF-κB activation, enhanced inflammatory responses, and reduced cell death sensitivity, contributing to disease pathogenesis in cancer and inflammatory conditions 34. In hypoxic tumors, RNF213-mediated CYLD/SPATA2 degradation suppresses necroptosis and triggers pyroptosis through NLRP3 inflammasome activation 4. Clinical Significance: Elevated SPATA2 expression correlates with poor prognosis in endometrial cancer, predicting reduced recurrence-free and disease-specific survival 5. These findings suggest SPATA2 is a potentially targetable node in inflammatory and neoplastic diseases.